Logo for DURECT Corp

DURECT Investor Relations Material

Latest events

Logo for DURECT Corp

Q2 2024

DURECT
Logo for DURECT

Q2 2024

13 Aug, 2024
Logo for DURECT

Q1 2024

13 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from DURECT Corp

Access all reports
DURECT Corp is a biopharmaceutical company engaged in the development of therapies using epigenetic modulation for the treatment of acute organ injury and chronic liver diseases. Its research focuses on new chemical entities, with a significant emphasis on its endogenous epigenetic regulator program. The company's pipeline includes products such as DUR-928, aimed at conditions like alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, designed for post-operative pain management; and Oradur, for chronic pain and attention deficit hyperactivity disorders. Additionally, DURECT manufactures and markets osmotic pumps for laboratory research and provides biodegradable polymers and excipients for the pharmaceutical and medical device industries. The company is headquartered in Cupertino, California, and its shares are listed on the Nasdaq.